To develop an optimized drug candidate for Chagas disease
current phase of drug development
updated 1 Jun 2021
In February 2016, Daiichi Sankyo and DNDi launched a high-throughput screening project of 40,000 compounds from Daiichi Sankyo with the goal of discovering anti-leishmaniasis and anti-Chagas disease compounds. With support from the Global Health Innovative Technology Fund (GHIT Fund), a two-year lead optimization collaboration between Daiichi Sankyo and DNDi was initiated in April 2020 to develop an optimized drug candidate for Chagas disease from the frontrunning series, in line with the DNDi Target Candidate Profile, including the elucidation of its mechanism.
News & press releases
Get our latest news, personal stories, research articles, and job opportunities.